- Home
- ERH vs GNLX Comparison
ERH vs GNLX Comparison
Compare ERH & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERH
- GNLX
- Stock Information
- Founded
- ERH 2004
- GNLX 2001
- Country
- ERH United States
- GNLX United States
- Employees
- ERH N/A
- GNLX N/A
- Industry
- ERH Finance/Investors Services
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- ERH Finance
- GNLX Health Care
- Exchange
- ERH Nasdaq
- GNLX Nasdaq
- Market Cap
- ERH 108.0M
- GNLX 128.0M
- IPO Year
- ERH N/A
- GNLX 2023
- Fundamental
- Price
- ERH $12.66
- GNLX $5.28
- Analyst Decision
- ERH
- GNLX Strong Buy
- Analyst Count
- ERH 0
- GNLX 4
- Target Price
- ERH N/A
- GNLX $17.75
- AVG Volume (30 Days)
- ERH 23.2K
- GNLX 133.6K
- Earning Date
- ERH 01-01-0001
- GNLX 11-13-2025
- Dividend Yield
- ERH 8.85%
- GNLX N/A
- EPS Growth
- ERH N/A
- GNLX N/A
- EPS
- ERH N/A
- GNLX N/A
- Revenue
- ERH N/A
- GNLX N/A
- Revenue This Year
- ERH N/A
- GNLX N/A
- Revenue Next Year
- ERH N/A
- GNLX N/A
- P/E Ratio
- ERH N/A
- GNLX N/A
- Revenue Growth
- ERH N/A
- GNLX N/A
- 52 Week Low
- ERH $7.97
- GNLX $1.99
- 52 Week High
- ERH $10.91
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- ERH 62.42
- GNLX 68.04
- Support Level
- ERH $12.01
- GNLX $4.17
- Resistance Level
- ERH $13.07
- GNLX $5.72
- Average True Range (ATR)
- ERH 0.17
- GNLX 0.36
- MACD
- ERH 0.02
- GNLX 0.08
- Stochastic Oscillator
- ERH 59.62
- GNLX 73.03
About ERH Allspring Utilities and High Income Fund
Allspring Utilities and High Income Fund is a diversified closed-end management investment company. Its investment objective is to seek a high level of current income and moderate capital growth, with an emphasis on providing tax-advantaged dividend income. The company allocates a majority of its total assets to a sleeve that places a focus on common, preferred, and convertible preferred stocks of utility companies and the rest of its total assets to a sleeve of U.S. dollar denominated below investment grade (high yield) debt.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.